



Institute
for
Scientific
Communications

ADDI-2018

Inaugural Asian Conference on Drug-Drug Interactions

Pioneer Lectures: Tools and Experimental Approaches for Assessment of Drug-drug Interactions; Regulatory Requirements for Drug-drug Interaction Evaluation; Transporter-mediated Drug-drug Interactions; Drug Metabolizing Enzyme-mediated Drug-drug Interactions; Atypical Drug-drug Interactions; Novel Technologies for the Evaluation of Drug-drug Interactions; Herb-drug Interactions

December 3-6, 2018

Venue: Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

REGISTRATION DISCOUNT UNTIL November 3, 2018

ISC, INC.

9221 Rumsey Road, Suite # 8
Columbia, Maryland 21045 USA



Featuring the Following Experts: Albert P. Li; Joan Zuo; Kim Brouwer; Yuichi Sugiyama; Sylvia Zhao; Genfu Chen; Zhuohan Hu; Jingjing Yu; Ming Huang; Sumito Ito; Ryuta Asaumi; Kotaro Nishiyama; Naoki Ishiguro; Guangqing Xiao; Katsuhiko Kanda; Shoko Takeyama; K. Sandy Pang; Kazuya Maeda; Norihiko Iwasaki; Xiaomei Zhuang; Toru Takenaka; woin Lee; Nora Lee; Soo-Jin Kim; Li Di; Ru Yan; Chuang Lu; Kenneth Brouwer; Daisuke Tenmizu; Timothy Yung; Ge Lin; Huichang Bi; Chuan Li; Brian Tomlinson; Chonlaphat Sukasem; Yan Zhang, Simon Wong

ADDI-2018 is an event providing a comprehensive update on the status of the science of drug-drug interactions and its relevance to drug development. The conference will include a review on the current status of DDI potential of biologics, industrial perspectives and other relevant topics.

PLEASE VISIT US ONLINE AT WWW.IFSCOMM.ORG

Organizing Chairs:

Albert P. Li, APSciences/In Vitro ADMET Laboratories, Inc.
Yuichi Sugiyama, *RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN*
Joan Zuo, The Chinese University, Hong Kong
Genfu Chen, WuXi AppTec
Chuang Lu, Sanofi
Lilly Xu, ChemPartner

Monday, December 3, 2018:

Session 1:

Pioneer Lectures: Tools and Experimental Approaches for Assessment of Drug-drug Interactions
(Chair: Joan Zuo, The Chinese University, Hong Kong)

Mechanisms and Clinical Significance of Hepatic Drug-drug Interactions Involving Efflux Drug Transporters (*Kim Brouwer, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*)

Extrapolation of In Vitro Drug-drug Interaction Data to In Vivo Clinical Findings (*Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN; Yokohama, Japan*)

In Vitro Human-based Experimental Systems for the Evaluation of Drug-drug Interactions; Hepatocytes, Enterocytes and beyond (*Albert P. Li, IVAL; Columbia, MD, USA*)

Session 2:

Regulatory Requirements for Drug-drug Interaction Evaluation
(Chair: Genfu Chen, WuXi AppTec)

The Pre-clinical DDI Guidance: Comparison Between USA FDA, EU, Japan and China, (*Zhuohan Hu, Research Institute of Liver Disease (Shanghai) Co Ltd. Shanghai, China*)

DDI guidance: The Clinical Focus (*Sylvia Zhao, China Novartis Institutes of Biomedical Research, Shanghai, China*)

Mechanistic Analysis of the Risk of Pharmacokinetic Drug-drug Interactions with Drugs Recently Approved by the US Food and Drug Administration (*Jingjing Yu, University of Washington; Seattle, WA, USA*)

Clinical Trial on DDI Risk Assessment - Case Studies, (*Min Huang, Sun Yat-sen University, Guangzhou, China*)

Reception/Vendor presentations

Social event: Reception; Performance by Hong Kong Traditional Dancers

Tuesday, December 4, 2018:

Session 3:

Transporter-mediated Drug-drug Interactions
(Chair: Yuichi Sugiyama, *RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN*)

The In Vitro Assays for Evaluating BSEP Inhibition Potencies of Drugs (*Sumito Ito, Genomembrane, Kanagawa, Japan*)

Predicting Complex DDIs Related to CYP Induction and OATP Inhibition by PBPK Model of Rifampicin with its own Hepatic Uptake and Auto-induction, (*Ryuta Asaumi, Ono Pharmaceutical, Ibaraki, Japan*)

Application of PBPK Modeling to Renal OCT2 and MATEs mediated DDIs: Predicting Changes in Renal Clearance and Blood AUC Caused by the Transporter Inhibitors. (*Kotaro Nishiyama, Nippon Boehringer Ingelheim, Kobe, Japan*)

Quantitative Analysis of Complex Drug-drug Interactions using PBPK Models with In Vitro Inhibition Data: Repaglinide and Cerivastatin (*Soo-Jin Kim, CJ HealthCare, Seoul, Republic of Korea*)

Usefulness of a Model-based Approach for Estimating In Vitro P-glycoprotein Inhibition Potency in a Transcellular Transport Assay, (*Naoki Ishiguro, Nippon Boehringer Ingelheim, Kobe, Japan*)

Case Study on Renal Transporter mediated DDI: Weak Interactions between Metformin and Fampridine, an OCT2 but not MATE Substrate (*Guangqing Xiao, Takeda Pharmaceuticals International Co., Cambridge, MA, USA*)

Hepatocellular Disposition Profiling of Rosuvastatin and Pitavastatin in Sandwich-Cultured Human Hepatocytes: BCRP inhibitor, Ko143, Decreased not only Biliary Excretion but also Basolateral Efflux of Rosuvastatin (*Katsuhiko Kanda, Hitachi High-Technologies Corporation, Ibaraki, Japan*)

Social event: Tour of Chinese University of Hong Kong
Free afternoon

Wednesday, December 5, 2018

**Session 4:
Drug Metabolizing Enzyme-mediated Drug-drug
Interactions
(Chair: Chuang Lu, Sanofi)**

PBPK modeling to describe intestinal vs. liver handling and DDI (*K. Sandy Pang, University of Toronto, Toronto, Canada*)

Use of Cluster Newton Method to Obtain Reliable In Vivo K_i Values by Analyzing the Change in Pharmacokinetics of both Parent and Metabolites of Victim Compound (*Kazuya Maeda, The University of Tokyo, Tokyo, Japan*)

Assessment of CYP1A2 Inductive Potential of Edaravone, a New Drug Approved for ALS, and Necessity Judgment of the Clinical DDI Study (*Norihiko Iwazaki, Mitsubishi-Tanabe Pharma Corporation, Saitama, Japan*)

CYP3A5 Allosteric Activation and its Mechanism Research (*Xiaomei Zhuang, Beijing Institute of Pharmacology and Toxicology, Beijing, China*)

Prediction of Time-dependent DDI with CYP3A in the Liver and Intestine Based on the PBPK Modeling and Comparison with Data from Clinical DDI Study (*Toru Takenaka, Taiho Pharmaceutical Co., LTD., Tsukuba, Japan*)

**Session 5:
Atypical Drug-drug Interactions
(Chair: Lilly Xu, Chem Partner)**

Target-mediated Drug Disposition in Small Molecule Drugs: Its Role in Atypical Pharmacokinetic Non-linearity and DDI (*Woojin Lee, Seoul National University, Seoul, Korea*)

Physiologically-based Pharmacokinetic Analysis of Nonlinear Pharmacokinetics of Paclitaxel and Drug Interactions with other Drugs (*Nora Lee, Daewoong Pharmaceutical, Seoul, Republic of Korea*)

Recent Advances in Reaction Phenotyping to Access Victim Drug-Drug Interaction (*Li Di, Pfizer Inc., Groton, CT, USA*)

Application of In Vitro "Dissolution/permeation (D/P) System" to Predict Absorption-based Drug-drug Interaction (*Shoko Takeyama, Daiichi Sankyo RD Novare Co., Ltd; Tokyo, Japan*)

HLA, CYP, and DDI; the SCAR Determinant and Contributing Factors (*Chonlaphat Sukasem, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand*)

Unraveling Gut Microbiota-herb Interactions Employing 16S rRNA Microbial Sequencing and Metabolomics. (*Ru Yan, University of Macau, Taipa, Macao, China*)

Social event: Symposium banquet

Thursday, December 6, 2018

**Session 6:
Novel Technologies for the Evaluation of Drug-drug
Interactions
(Chair: Albert P. Li, IVAL)**

Novel In Vitro Methods for Clinical DDI Prediction (*Chuang Lu, Sanofi, Cambridge, MA, USA*)

Alterations in Bile Acid Transport in Human Hepatocytes as a Predictive Tool to Evaluate DILI Potential in Drug Development (*Kenneth Brouwer, BioIVT, Durham, NC, USA*)

Case Study for Improvements of CYP DDI Victim Risk GAP between Perspective and Retrospective Prediction Using New ADME Tools, Chimeric Mice (*Daisuke Tenmizu, Astellas Pharma Inc., Tsukuba, Japan*)

Drug-Vitamin Transporter Interaction: Are We Ready for a Thiamine Transporter (THTR2) Decision Tree? (*Yan Zhang, Incyte Corporation, Wilmington, DE, USA*)

Preclinical Evaluation of Drug-Drug Interaction Potential in Drug Discovery: Challenging the Status Quo (*Simon G. Wong, Genentech, South San Francisco, California, USA*)

**Session 7:
Herb-drug Interactions
(Chair: Joan Zuo, CUHK)**

East meet West: Overview of Herb-drug Interaction Research in Hong Kong (*Joan Zuo, CUHK, Hong Kong, China*)

A Pragmatic Approach to Review Herb-drug Interactions for Implementation of Integrative Medicine (*Timothy Yung, Hospital Authority of Hong Kong, Hong Kong, China*)

Beneficial Herb-drug Interaction in the Combinational Use of Herbal Polyoxypregnanes with Paclitaxel (*Ge Lin, The Chinese University of Hong Kong, Hong Kong, China*)

Herbal Medication and Liver Diseases (*Huichang Bi, Sun Yat-sen University, Guangzhou, China*)

Herbal Medication Mediated CYP or Transporter based DDI and PBPK Modeling for Risk Assessment (*Chuan Li, Chinese Academy of Science, Beijing, China*)

Herb-drug Interactions – Do they Matter in the Clinic? (*Brian Tomlinson, The Chinese University of Hong Kong, Shatin, Hong Kong, China*)

Closing Remarks (Albert P. Li, IVAL)

**SEE REGISTRATION FORM
BELOW**

REGISTRATION FORM: ADDI-2018

Or please register online at: <http://www.ifscomm.org/>

A. Credit Card Information:

**Required fields to be completed*

*American Express _____ VISA _____ MC _____

*Cardholder Name:

*Cardholder Billing Address:

*Cardholder Billing City:

*Cardholder Billing State / Zip (Postal) Code:

*Cardholder Phone #: _____

*Cardholder Email: _____

*Card Number: _____

*Expiration Date: _____

*3 or 4 Digit Security Code: _____

*Amount: U.S. \$ _____

ADDI-2018 Registration Fee Schedule

Academic and government institutions receive 50% discount per person
Exhibiting companies receive a 50% discount per person
(with a paid Exhibitor registration)

Event Name	Registration Fee	Registration Fee	Exhibitor Fee
	Until Nov 3, 2018	After Nov 3, 2018	
ADDI-2018	\$ 1,250.00	\$ 1,500.00	\$ 2,000.00



Institute
for
Scientific
Communication

B. Registrant Information:

Dr. _____ Mr. _____ Ms. _____

Please type your name as you wish it to appear on your name badge

PLEASE PRINT

Last Name First Name Mid. Initial

Job Title

Company/Agency/Institution

Address 1

Address 2

City State Postal Code

Country

Telephone FAX

Email Address

How did you hear about this meeting?

Colleague _____ Web Site _____

Brochure _____ Calendar Listing _____

E-mail _____ Journal Ad _____

ALL PRICES ARE SHOWN IN US CURRENCY